MIRABEGRON CINFAMED 50 mg PROLONGED-RELEASE TABLETS

2. What you need to know before taking Mirabegron Cinfamed

Do not take Mirabegron Cinfamed

• if you are allergic to mirabegron or any of the other ingredients of this medication (listed in section 6).
• if you have uncontrolled high blood pressure.

Warnings and precautions

Consult your doctor or pharmacist before starting to take mirabegron:

• if you have problems emptying your bladder or have a weak urine stream, or if you are taking other medications for the treatment of overactive bladder or neurogenic detrusor overactivity, such as anticholinergic medications.
• if you have kidney or liver problems. Your doctor may need to reduce the dose or tell you not to take mirabegron, especially if you are taking other medications such as itraconazole, ketoconazole (for fungal infections), ritonavir (for HIV/AIDS), or clarithromycin (for bacterial infections). Inform your doctor about the medications you are taking.
• if you have a known abnormality in your ECG (heart study) such as a prolonged QT interval, or if you are taking any medication known to cause such an abnormality, such as:

• medications used for heart rhythm disorders, such as quinidine, sotalol, procainamide, ibutilide, flecainide, dofetilide, and amiodarone;
• • medications used for allergic rhinitis;
  • antipsychotic medications (for mental illnesses) such as thioridazine, mesoridazine, haloperidol, and chlorpromazine;
  • anti-infective agents such as pentamidine, moxifloxacin, erythromycin, and clarithromycin.

Mirabegron may cause your blood pressure to increase or worsen if you have a history of high blood pressure. It is recommended that your doctor check your blood pressure while you are taking this medication.

Children and adolescents

Do not give this medication to children and adolescents under 18 years of age for the treatment of overactive bladder, as the safety and efficacy of mirabegron in this population have not been established.

This medication should not be used in children under 3 years of age for the treatment of neurogenic detrusor overactivity.

Other medications and Mirabegron Cinfamed

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medication.

Mirabegron may affect how other medications work, and other medications may affect how this medication works.

• Tell your doctor if you are using thioridazine (a medication for mental illnesses), propafenone, or flecainide (medications for heart rhythm disorders), imipramine, or desipramine (medications used for depression). These specific medications may require your doctor to adjust the dose.
• Tell your doctor if you are using digoxin (a medication for heart failure or heart rhythm disorders). Your doctor will measure the levels of this medication in your blood. If the level is outside the allowed range, your doctor will adjust the dose of digoxin.
• Tell your doctor if you are using dabigatran etexilate (a medication used to reduce the risk of stroke or systemic embolism in patients with irregular heartbeat (atrial fibrillation) and additional risk factors). Your doctor may need to adjust the dose of this medication.

Pregnancy and breastfeeding

If you are pregnant, think you may be pregnant, or plan to become pregnant, do not take this medication.

If you are breastfeeding, consult your doctor or pharmacist before using this medication.

It is likely that this medication will pass into breast milk. You and your doctor should decide whether to take mirabegron or breastfeed. Never do both.

Driving and using machines

There is no information to suggest that this medication affects your ability to drive or use machines.

3. How to take Mirabegron Cinfamed

Follow your doctor's instructions for taking this medication exactly. If you are unsure, consult your doctor or pharmacist again.

Use in adults with overactive bladder

The recommended dose is one 50 mg tablet by mouth once a day. If you have kidney or liver problems, your doctor may need to reduce the dose to one 25 mg tablet by mouth once a day. You should take this medication with liquid and swallow the tablet whole. Do not crush or chew the tablet. Mirabegron can be taken with or without food.

Use in children and adolescents (aged 3 years and older) with neurogenic detrusor overactivity

Take this medication by mouth once a day. You should take this medication with liquid and swallow the tablet whole. Do not crush or chew the tablet. Mirabegron should be taken with food. Your doctor will tell you what dose your child should take. The doctor will calculate the correct dose for the patient based on their body weight. You should follow their instructions carefully.

If you take more Mirabegron Cinfamed than you should

If you have taken more tablets than you were told to, or if someone else has taken your tablets by mistake, contact your doctor, pharmacist, or hospital immediately.

Symptoms of overdose may include a strong heartbeat, increased heart rate, and increased blood pressure.

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount taken.

If you forget to take Mirabegron Cinfamed

If you forget to take your medication, take the missed dose as soon as you remember. If it is less than 6 hours until your next scheduled dose, skip the missed dose and continue taking the medication at the usual time.

Do not take a double dose to make up for missed doses. If you miss several doses, consult your doctor and follow their recommendations.

If you stop taking Mirabegron Cinfamed

Do not stop taking mirabegron early if you do not see an immediate effect. Your bladder may need time to adjust. You should continue taking your tablets. Do not stop taking them when your bladder symptoms improve. Stopping treatment may cause the symptoms of overactive bladder or neurogenic detrusor overactivity to return.

Do not stop taking mirabegron without consulting your doctor first, as the symptoms of overactive bladder or neurogenic detrusor overactivity may return.

If you have any other questions about the use of this medication, ask your doctor or pharmacist.

4. Possible side effects

Like all medications, this medication can cause side effects, although not everyone gets them.

The most serious side effects may include irregular heartbeat (atrial fibrillation). This is an uncommon side effect (affecting up to 1 in 100 people), but if it occurs, stop taking the medication immediately and seek urgent medical advice.

Consult your doctor if you experience headache, especially sudden, migraine-like (palpitations). They may be signs of very high blood pressure.

Other side effects include:

Common(may affect up to 1 in 10 people)

• Urinary tract infection (urinary tract infections)
• Headache
• Dizziness
• Increased heart rate (tachycardia)
• Feeling of dizziness (nausea)
• Constipation
• Diarrhea

Uncommon(may affect up to 1 in 100 people)

• Vaginal infection
• Bladder infection (cystitis)
• Feeling of heartbeat (palpitations)
• Heart rhythm problems (atrial fibrillation)
• Indigestion (dyspepsia)
• Stomach infection (gastritis)
• Itching, rash, or hives (urticaria, rash, macular rash, papular rash, pruritus)
• Swelling of the joints
• Itching in the vulva or vagina (vulvovaginal pruritus)
• Increased blood pressure
• Increased liver enzymes (GGT, AST, and ALT)

Rare(may affect up to 1 in 1,000 people)

• Swelling of the eyelids (eyelid edema)
• Swelling of the lips (lip edema)
• Inflammation of small blood vessels that mainly affects the skin (leukocytoclastic vasculitis)
• Small purple spots on the skin (purpura)
• Swelling of the inner layers of the skin caused by fluid accumulation, which can affect any part of the body, including the face, tongue, or throat, and can cause difficulty breathing (angioedema)
• Inability to empty the bladder completely (urinary retention)

Very rare(may affect up to 1 in 10,000 people)

• Very high blood pressure (hypertensive crisis)

Frequency not known(cannot be estimated from the available data)

• Insomnia
• Confusion

Mirabegron may increase the risk of not being able to empty your bladder if you have a blockage of the bladder outlet or if you are taking other medications for the treatment of overactive bladder. Tell your doctor immediately if you are unable to empty your bladder.

Reporting side effects

If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medicines Surveillance System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medication.

5. Storage of Mirabegron Cinfamed

Keep this medication out of the sight and reach of children.

Do not use this medication after the expiration date stated on the packaging after EXP. The expiration date is the last day of the month indicated.

This medication does not require special storage conditions.

Medications should not be disposed of via wastewater or household waste. Dispose of the packaging and any unused medication in the SIGRE collection point at the pharmacy. Ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.

6. Contents of the pack and further information

Composition of Mirabegron Cinfamed

The active substance is mirabegron. Each tablet contains 50 mg of mirabegron.

The other ingredients are:

• Core of the tablet: High molecular weight macrogol, microcrystalline cellulose, hypromellose, hydroxypropylcellulose, butylhydroxytoluene, magnesium stearate, and anhydrous colloidal silica.
• Coating material: Poly(vinyl alcohol), titanium dioxide, macrogol, talc, yellow iron oxide (E172), and red iron oxide (E172)

Appearance of the product and packaging

Light yellow, oblong, biconvex, film-coated tablet, approximately 5.7 x 12.8 mm in size.

It is available in Al-OPA/Al/PVC blisters. Each pack contains 30 prolonged-release tablets.

Marketing authorization holder and manufacturer

Marketing authorization holder

Laboratorios Cinfa, S.A.

Carretera Olaz-Chipi, 10, Polígono Industrial Areta

31620 Huarte (Navarra) – Spain.

Manufacturer

Laboratorios Cinfa, S.A.

Carretera Olaz-Chipi, 10, Polígono Industrial Areta

31620 Huarte (Navarra) – Spain

Or

Pharmadox Healthcare Ltd.

KW20A Kordin Industrial Park,

Paola PLA 3000, Malta.

Or

Adalvo Limited

Life Sciences Park, Building 1, Level 4,

Sir Temi Zammit Buildings, San Gwann,

SGN 3000, Malta

Date of last revision of this package leaflet: January 2025

Detailed information about this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).

You can access detailed and updated information about this medication by scanning the QR code included in the package leaflet and packaging with your smartphone. You can also access this information at the following internet address: https://cima.aemps.es/cima/dochtml/p/90106/P_90106.html

QR code to: https://cima.aemps.es/cima/dochtml/p/90106/P_90106.html